EUVIMEDSkopri EUVIMED
VergleichsstudieOpen access · CC BY-NC 4.0

Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case‐Control Study and Comparison With Pre‐ and Post‐COVID‐19 Seasons in a Tertiary Pediatric Hospital

Fuensanta Guerrero-Del-Cueto, Sara Lobato-Lopez, Diego Lozano-Duran, Blanca Sanchez-Duran, Lucia Ramirez-Martin, Begoña Esteban-San-Narciso, Sara Sosa-Hernandez, Laura Martin-Pedraz, David Moreno-Perez, Isabel Leiva-Gea, Esmeralda Nuñez-Cuadros

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71059 ↗

At a glance

Vergleichsstudie in Pediatric Pulmonology, 2025. Written by Fuensanta Guerrero-Del-Cueto and 10 co-authors. Institution: Department of Paediatrics at the Malaga Mother-and-Child Hospital, Hospital Regional Universitario de Malaga, Malaga, Spain. Major MEDLINE topics: Respiratory Syncytial Virus Infections, COVID-19, Antibodies, Monoclonal, Humanized, Hospitalization. Cited 5 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: The authors received no specific funding for this study..

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Introduction

This study evaluates nirsevimab's real‐world effectiveness in preventing respiratory syncytial virus (RSV) bronchiolitis hospitalizations after its introduction in Andalusia's immunization schedule, compares clinical outcomes between immunized and non‐immunized infants (2023–2024), and examines RSV seasonality pre‐ and post‐COVID‐19.

Methods

Retrospective single‐center case‐control study conducted at a tertiary pediatric hospital (Malaga Regional University Hospital). Infants hospitalized for PCR‐confirmed RSV bronchiolitis during the first season after nirsevimab introduction were matched with two controls born on the same day. Immunization status, demographic data, and clinical outcomes were analyzed. As a secondary analysis, clinical characteristics and adverse outcomes of immunized and non‐immunized RSV bronchiolitis cases from the 2023–2024 season were compared with four previous periods: pre‐pandemic decade (04/2010–03/2020), first pandemic season (04/2020–03/2021), second pandemic season (04/2021–03/2022) and third pandemic season (04/2022–03/2023).

Results

Nirsevimab showed 91.5% effectiveness (95% CI: 71.8%–97.4%) in reducing RSV bronchiolitis hospitalizations, which decreased 72.4% from the pre‐pandemic average and 82.4% from 04/2022–03/2023. Intensive‐care‐unit admissions were significantly higher in non‐immunized infants (60.0% vs. 26.1%, p = 0.04), with no differences in bacterial superinfection, oxygen requirement and length‐of‐stay.

Conclusions

Nirsevimab significantly reduced RSV bronchiolitis hospitalizations during its first season of use. The study also highlights shifts in RSV seasonality trends influenced by the COVID‐19 pandemic, highlighting the need for ongoing surveillance to adapt public health strategies.

Subjects

MeSH terms (MEDLINE)

Respiratory Syncytial Virus InfectionsCOVID-19Antibodies, Monoclonal, HumanizedHospitalizationAntiviral AgentsBronchiolitis, ViralHumansCase-Control StudiesMaleRetrospective StudiesFemaleInfantTertiary Care CentersSeasonsHospitals, PediatricSeverity of Illness Index

Author keywords

bronchiolitisepidemiologyimmunizationnirsevimabrespiratory syncytial virus (RSV)

Substances

Antibodies, Monoclonal, HumanizedAntiviral Agents

Authors and institutions

  • Department of Paediatrics at the Malaga Mother-and-Child Hospital, Hospital Regional Universitario de Malaga, Malaga, Spain.
  • Facultad de Medicina, Universidad de Malaga, Malaga, Spain.
  • Instituto de Investigacion Biomedica de Malaga (Biomedical Research Institute of Malaga), Malaga, Spain.
  • Consejería de Salud y Familias de la Junta de Andalucia, Seville, Spain.

Funding

  • The authors received no specific funding for this study.

Cite

APA

Guerrero-Del-Cueto, F., Lobato-Lopez, S., Lozano-Duran, D., Sanchez-Duran, B., Ramirez-Martin, L., Esteban-San-Narciso, B., Sosa-Hernandez, S., Martin-Pedraz, L., Moreno-Perez, D., Leiva-Gea, I., & Nuñez-Cuadros, E. (2025). Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case‐Control Study and Comparison With Pre‐ and Post‐COVID‐19 Seasons in a Tertiary Pediatric Hospital. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71059

Vancouver

Guerrero-Del-Cueto F, Lobato-Lopez S, Lozano-Duran D, Sanchez-Duran B, Ramirez-Martin L, Esteban-San-Narciso B, et al. Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case‐Control Study and Comparison With Pre‐ and Post‐COVID‐19 Seasons in a Tertiary Pediatric Hospital. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71059

BibTeX
@article{GuerreroDelCueto2025,
  author = {Guerrero-Del-Cueto, Fuensanta and Lobato-Lopez, Sara and Lozano-Duran, Diego and Sanchez-Duran, Blanca and Ramirez-Martin, Lucia and Esteban-San-Narciso, Begoña and Sosa-Hernandez, Sara and Martin-Pedraz, Laura and Moreno-Perez, David and Leiva-Gea, Isabel and Nuñez-Cuadros, Esmeralda},
  title = {Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case‐Control Study and Comparison With Pre‐ and Post‐COVID‐19 Seasons in a Tertiary Pediatric Hospital},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71059}
}
Start for free →